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Diabetes mellitus is a chronic disease with great social
and economical impact. In all its forms, it affects
nearly 200 million people worldwide (1). Type 1
diabetes (T1D) represents 10% of all cases. Because
of the increase in obesity in developed countries, the
prevalence of type 2 diabetes (T2D) has been rising very
rapidly, affecting children and adolescents.
T1D and advanced T2D are caused by a progressive
loss of functional pancreatic β-cell mass within
the pancreatic islets. The extraordinary results of
the Edmonton protocol have shown that human
pancreatic islet transplantation can normalize glycemic
control of insulin-dependent diabetic patients (2).
Nevertheless, this therapeutic option does not represent
a significant clinical benefit for all diabetic patients;
the demand of islets for transplantation is very high
and human donor pancreas for isolation of islet
grafts is limited. Furthermore, transplants do last no
longer than 2 yr and are accompanied by significant
side effects as a consequence of lifelong aggressive
immunosuppression (3). Therefore, intensive search
for new sources for β-cell replacement has been
undertaken. Regeneration of existing mature β-cells
and replacement of insulin-producing cells are current
research lines that could possibly solve the problem of
islet shortage. Differentiation of embryonic stem (ES)
cells has been thoroughly investigated; however, results
are not yet satisfactory (4–6). Adult stem/progenitor
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cells of pancreatic and extrapancreatic origin have
been demonstrated to differentiate in vitro into insulin-
producing phenotypes (7).
Bone marrow stromal cells (BM-MSC) display adult
stem cell character (8). Despite their mesodermal
origin, the capacity of BM-MSC to restore β-cell
function has been demonstrated by several groups (9,
10). Notwithstanding, the fate and function of in vitro
cultivated BM-MSC and in vivo transplanted BM-MSC
appear to diverge.
This article focuses on recent experiments on BM-
MSC as a suitable source for β-cell replacement and its
putative therapeutic potential in diabetes mellitus.
Potential sources for cell-based therapy in
diabetes mellitus
ES cells
ES cells are non-committed cells with infinite self-
renewal capacity, which, under specific conditions, are
able to differentiate into cells of any tissue. It has been
shown that ES cells may provide an unlimited supply of
pancreatic β-cells (11). In the past 2 yr, important steps
have been taken toward differentiation and isolation
of endodermal pancreatic precursor cells from rodent
and also human ES cells with subsequent generation
of insulin-producing phenotypes (4–6). Regrettably,
differentiation efficacy is low and, so far, no glucose-
responsive insulin secretion was observed in these
phenotypes.
In spite of the enormous potential of ES cells, major
ethical concerns regarding the harvesting of human ES
cells, together with the associated tumorigenic risk of
developing teratocarcinoma (12), have been delaying
the breakthrough of ES cells for the development of
new forms of regenerative medicine. Nevertheless, in
the diabetes field, ES cell investigation has been crucial
to uncover developmental steps of human pancreatic
endocrine cells in vitro because almost all data available
are based on animal models.
Adult stem cells within and outside the pancreas
Identification, isolation, and in vitro proliferation of
stem/progenitor cells within the endocrine pancreas
might represent an ideal solution for β-cell replacement
in T1D. Previous experiments in vitro and/or in vivo
described the existence of precursor cells with poten-
tial to differentiate into insulin-producing phenotypes
in the pancreatic islets (13, 14), ducts (15), and acini
(16), as well as within the adult and fetal pancreas. Both
mechanisms of bona fide proliferation and neogenesis
have been implicated in the generation of new β-cells in
response to specific stimuli. Yet, the existence of a ‘true’
pancreatic endocrine stem cell has been strongly ques-
tioned. Genetic lineage tracing studies have demon-
strated that physiological β-cell regenerative processes
occur through replication of existing mature β-cells and
not via differentiation of pancreatic progenitor cells
(17). This conflicts with recent studies that corrobo-
rate the existence of pancreatic precursor cells (18, 19).
Using a unique pancreatic injury model, Xu et al. has
convincingly demonstrated the de novo generation of β-
cells from pancreatic progenitor cells through reactiva-
tion of neurogenin 3, a marker of pancreatic endocrine
precursor cells in the developing pancreas (20).
After intensive investigation in the last few years,
it is now well accepted that populations of adult cells
residing in a specific tissue are not necessarily com-
mitted to a specific cell lineage. Despite discussion on
mechanisms and pathways responsible for differenti-
ation (neogenesis, differentiation, transdifferentiation,
or cell fusion) (21), in vitro and in vivo experiments have
shown that adult stem cells from different origins could
be induced to replace or regenerate injured tissues by
overwhelming germ layer boundaries (7).
Extrapancreatic stem/progenitor cells from liver
(22, 23), central nervous system (24), and bone
marrow (BM) (9, 10) have been described to express
and produce insulin in vitro, when subjected to
specific biological conditions or genetic manipulation
strategies. While some of these studies claimed
the potential of differentiated cells to ameliorate
hyperglycemia in diabetic animal models, the in vitro
insulin secretion is limited and glucose-sensing response
is reduced compared with native β-cells, which means
that complete differentiation process into mature β-cell-
like phenotypes could not be achieved ex vivo and the
mechanisms of in vivo amelioration are unexplained yet.
Umbilical cord-derived mesenchymal stem cells (UC-
MSC) have been suggested as an attractive source for
the cell-based therapy of diabetes mellitus. In previous
experiments, isolated UC-MSC have been found to
reduce insulitis and ameliorate glycemic control when
transplanted into T1D mouse models (25), but no
study has so far reported differentiation of UC-MSC
into insulin-producing phenotypes.
Studies on peripheral blood cells with the capac-
ity to transdifferentiate into insulin cell types are
few and could never be reproduced (26). BM-derived
hematopoietic stem cells (HSC), which have been a
valuable source for the cellular treatment of several
hematological diseases, showed controversial results in
diabetic mice models (27, 28). The observation that
HSC differentiate in vivo, into insulin-positive cells,
was never replicated (28). Moreover, it has been sug-
gested that the most probable effect of infused HSC is
to induce regeneration of the injured islets in diabetic
pancreas (27).
In humans, only one clinical trial has described a
successful therapeutic outcome after autologous non-
myeloablative HSC transplantation in newly diagnosed
T1D. Indeed, improved peak stimulated C-peptide
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levels, decreased glutamic acid decarboxylase (GAD)
antibodies, and prolonged insulin independence were
observed in a significant number of patients (29).
Because of the administration of immunosuppressive
agents and antithymocyte globulin to these patients, it
is impossible, in a context of autoimmune disease, to
evaluate the beneficial effects of HSC transplantation
vs. immunomodulation. Moreover, it is questionable if
such an intervention with well-known acute and long-
term complications is ethically acceptable in a treatable
disorder like T1D.
Mesenchymal stem cells
Mesenchymal cells are part of the ‘stroma’, which,
in turn, corresponds to the supporting framework
of each tissue or organ (Fig. 1). Stromal cells ensure
major support functions, including a three-dimensional
structure (fibroblasts, collagen, and vascular cells),
nutritional source (blood supply), and tissue repair
(endothelial cells, immune cells, mesenchymal cells,
growth factors, and cytokines). These properties have
raised the interest of investigators on stromal cells for
regenerative medicine.
Mesenchymal stromal cells are multipotent cells
The multilineage differentiation capacity of mesenchy-
mal stromal cells (MSC) has been initially described in
the BM (8). BM includes at least two distinct popula-
tions of cells, both with high plasticity: hematopoietic
CD34+ stem cells (HSC) –the precursors of all mature
blood cells (30) –and mesenchymal CD34− stem
cells (BM-MSC). BM-MSC are a specific population
within marrow stromal cells that have been shown
to differentiate into mesodermal lineages, including
fat, bone, cartilage, muscle and also toward epithelial,
neuroectodermal, and endodermal phenotypes. More
recently, cells with MSC properties have been identi-
fied in adipose tissue and umbilical cord, placenta, and
synovium (31).
Characteristics of BM-MSC
Because of their migration and homing capacity, mes-
enchymal cells play a fundamental role in embryonic
morphogenesis, tissue repair, and regeneration (32). In
BM-MSC, expression of several chemokine receptors,
such as Cxrc4 receptor, for stem cell factor 1 strongly
suggest this property (33). Furthermore, extensive in
vitro studies have demonstrated that BM-MSC can
exert profound immunosuppressive effects via mod-
ulation of cellular immune pathways (34–36). Addi-
tionally, the immunophenotype of BM-MSC (MHCI+,
MHCII−, CD80−, CD86−, and CD40−) is considered
non-immunogenic. This feature may allow for allo-
genic transplantation of the cells with no need for
immunosuppression. On the other hand, the stromal
supporting nature of MSC offers an additional advan-
tage for maintenance of the grafts or regeneration of
injured tissues.
Isolation of BM-MSC
According to the International Society for Cellular
Therapy, MSC can be distinguished by in vitro plastic
adherence, self-renewal, specific surface markers, and
Fig. 1. The bone marrow-derived mesenchymal stem cell (BM-MSC) properties: most important features of BM-MSC, which renders these
cells very attractive for cell-based therapies and in particular for β-cell replacement in type 1 diabetes..
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differentiating capacity into multiple mesenchymal
lineages following engraftment (37). Yet, so far, there is
no consensus marker panel that allows for prospective
identification of MSC from the in vitro marrow stromal
cell population. Recently, it has been reported that
neuro ganglioside GD2 surface marker is expressed
in BM-MSC and not in other marrow stromal cells
(38). Moreover, SSEA-4, a glycolipid antigen marker
of human ES cells (39) as well as the nucleolar protein
nucleostemin are suggested as adult MSC markers (40).
Are adult BM-MSC a promising source for
β-cell replacement?
In vitro and in vivo reprogramming of adult cells. Repro-
gramming adult somatic cells implicates induction or
repression of key regulatory genes, which are able to
switch cells from one lineage into another or to dedif-
ferentiate a mature phenotype back to a more primitive
state to obtain pluripotency.
In recent pioneering experiments, mouse and human
fibroblasts have been successfully reprogrammed into
ES-like stem cell lines. These induced pluripotent stem
cells (iPS) were generated by in vitro retroviral trans-
duction of four transcription factors (Oct3/4, Sox2,
c-Myc, and Klf4) that completely modified the epige-
netic signature and phenotype of these cells (41, 42).
Using the same techniques, murine liver and stomach
cells have also been reprogrammed into iPS cells (43).
Moreover, reprogramming of adult exocrine pancre-
atic cells into functional β-cells was recently achieved
by re-expressing a combination of key regulatory genes
(Ngn3, Pdx1, and MaFA) in living adult animals. A
great advantage of this in vivo strategy was to maintain
the viral transduced exocrine cells in their native envi-
ronment, which may favor maturation and survival of
newly reprogrammed β-cells (44).
Because of their multipotent properties, MSC may
have an almost unlimited differentiation potential once
they have been reprogrammed. This might be achieved
by specific culture conditions, genetic induction of
key transcriptions factors, or more recently through
epigenetic modifications.
Reprogramming BM-MSC into insulin-producing
phenotypes
In recent years, an increasing body of evidence suggests
that BM-MSC have the potential to differentiate in
vitro into insulin-producing cells in mouse (9, 10) and
human systems (45, 46) and to revert hyperglycemia
at least in diabetic mouse models (9, 10, 45). Initial
results have been achieved by ex vivo expansion of
plastic adherent BM-MSC and prolonged endocrine
cultivation conditions (9, 10). More recently, the
endocrine β-cell-like phenotype was obtained by forced
expression of a pancreatic endocrine key regulator,
Pdx-1, in primary BM-MSC, with higher differentiation
efficiency (45). Furthermore, epigenetic modification
could induce differentiation of mouse BM-MSC into
insulin-producing cells, even in a glucose-sensing
manner (47). Nevertheless, efficacy of BM-MSC
differentiation is low and highly variable. The most
important limitation at the current state of knowledge
is the insulin secretion capacity of these cells, which
is far from native β-cells. While several studies have
demonstrated the potential of endocrine-differentiated
BM-MSC to produce and secrete insulin in a glucose-
sensing manner, insulin amount is still significantly
lower compared with mature β-cells (9, 10, 45, 47).
This might be related to donor-specific variabil-
ity, heterogeneity of MSC preparations, and non-
optimized differentiation protocols. Also, there might
be unknown BM-MSC populations with suitable
endocrine commitment to be found. In an attempt to
overcome such issues, we used a well-characterized cell
line, the telomerase-immortalised human adult bone
marrow-derived mesenchymal stem cell line (hMSC-
TERT), as a human BM-MSC model to investigate
the molecular mechanisms of endocrine differentiation
in MSC (Limbert C, Pa¨th P, Ebert R, Rothham-
mer V, Kassem M, Jakob F, Seufert J, unpublished
data). These cells were able to induce insulin in
response to specific culture conditions or via ectopic
expression of two major pancreatic endocrine genes,
Ngn3 and/or Pdx1. Specifically, our data indicate that
Ngn3 transcription factor is involved in Pdx1 and
insulin expression in hMSC-TERT, thus mimicking
the pancreatic endocrine transcription factor cascade
in the developing pancreas. Still, insulin secretion was
reduced and no response to glucose stimulation was
observed, which indicates reduced endocrine differ-
entiation capacity. Although hMSC-TERT display
‘endodermal prepatterning’ features, molecular tools
for the glucose-sensing machinery are missing in this
cell line. In vivo experiments could favor the endocrine
maturation of modified hMSC-TERT. Moreover, a
different combination of key regulatory genes might be
more adequate to obtain functional β-cell-like pheno-
types out of this population.
Anyhow, it is well accepted that independently
of the protocol and of the MSC population or
donors, reprogramming BM-MSC into functional
insulin-producing phenotypes in vitro requires several
important biological steps presented in Table 1.
Transplantation of adult BM-MSC into diabetic
mouse models
The direct transplantation of donor BM-MSC into
diabetic mice have convincingly demonstrated that
the major effect of BM-MSC infusion is to enhance
the number of endogenous mouse β-cells with
increase of mouse insulin and amelioration of
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Table 1. Major biological steps for reprogramming
BM-MSC into functional insulin cell-types
1. Gene expression markers for:
(i) Endodermal patterning of MSC: ABCG2, Cxcr4, Thy-1,
Foxa2, Sox17, Isl1, Hlxb9
(ii) Endocrine precursor cells: Ngn3, NeuroD, Nkx6.1,
Pax4
(iii) Mature β-cell
Key regulators of insulin expression-Pdx1 and Maf-A
Proinsulin (Ins)
Glucose transporter-Glut2
Glucose sensing-machinery- Glucokinase (Gck)
2. Protein synthesis
Insulin and/or C-peptide
3. Insulin secretion in response to glucose challenge in vitro
4. Improvement of hyperglycemia in diabetic animal
models and/or humans after engraftment of
insulin-producing phenotypes
5. Excision of the implanted cells leads to hyperglycemia
in the diabetic models
Expression of early endodermal markers in isolated adult
BM-MSC indicates the presence of suitable BM-MSC cell
sub-population. After the endocrine differentiation process,
expression of major regulatory transcription factors is
mandatory to recognize endocrine precursor phenotypes or
mature β-cells. The function of insulin-producing phenotypes
is assessed by the expression of insulin gene, specific
glucose transporter and glucose sensing factors, as well
as production, storage, and secretion of insulin protein in a
glucose-dependent manner. In vivo, these cells should revert
hyperglycemia in overt diabetic animal models and excision
of the engrafted cells triggers hyperglycemia.
hyperglycemia (48, 49). In contrast to previous
findings (28), differentiation of donor BM-MSC into
insulin-producing cells seems to be rare. Interestingly,
transplantation of in vitro endocrine-differentiated BM-
MSC into streptozotocin injured non-obese diabetic
mice increases insulin and C-peptide levels as well as
improves glycemic control. Nevertheless, as shown by
hyperglycemia after excision of the transplant, there is
no regeneration of endogenous mouse β-cells (10, 45).
These observations strongly suggest that, in vivo, fate
and function of endocrine-differentiated BM-MSC are
distinct from that of directly infused BM-MSC. Yet,
both can either revert or ameliorate diabetes.
At this point, some reflection should be made to
establish which mechanism is more suitable to be
adopted in cell-based strategies: cell reprogramming
with consecutive cell replacement or in situ induction
of β-cell regeneration.
Other promising approaches to cure T1D
mellitus
In vivo restoration of β-cell mass might prove beneficial
for the reversal of hyperglycemia, but protection
of the expanded β-cells from ongoing autoimmune
destruction is equally important to cure T1D mellitus.
The efficacy of immunosuppressive agents such as
prednisone, azathioprine, and cyclosporine to suppress
T lymphocytes in T1D patients has been thoroughly
evaluated (50, 51). Although slower decline in C-
peptide levels could be observed in these patients,
withdrawal of the drugs led to progression ofβ-cell mass
destruction, which would implicate lifelong immuno-
suppression with all known chronic complications.
More targeting immunomodulatory approaches
have been developed and are now on early phase
clinical trials. Treatment with either a peptide of
the heat-shock protein 63, Diapep277® (Andromeda
Biotech Ltd.’s, Yavne, Israel), an autoantigen with
immunomodulatory properties, or anti-CD3 antibody
has been effective in reducing insulitis and insulin
requirements in newly diagnosed T1D mice and
humans (52, 53). Results of a most recent clinical trial
revealed that vaccination with two dose of recombinant
GAD65 peptide, in early diagnosed type 1 diabetics
(< 6 months), induces preservation of residual β-cell
mass. This seems to result from stimulation of an
antigen-specific T-cell population and modulation of B-
cell memory (54). Similar to anti-CD3 treatment, GAD
vaccination slowed the decline of stimulated C-peptide
level, conferring a metabolic benefit after 18 months
of trial (53). In contrast to anti-CD3 therapy, no
reduction in insulin dose requirements was observed in
treated patients and no side effects were detected.
Yet, none of the described immunomodulatory
approaches has been sufficient for inducing insulin
independence.
Conclusion and perspectives
While cell-based therapy has still a fairly long way to go
in order to deliver a full response to T1D, there is still
room for exogenous insulin strategies developments.
Using nanoparticle systems, new concepts of glucose-
sensing insulin release are being tested on diabetic
animal models. SmartInsulin aims at being a once-a-
day subcutaneous insulin formulation liberated in a
glucose-regulated manner. Then again, the existence
of molecular signals other than glucose that could
unnecessarily release insulin into the circulation must be
certified to avoid dangerous bursts of insulin. Whereas
Smart particle delivery systems might represent a
relevant alternative in the treatment of T1D, it does
not comprise the key to insulin independence.
Because of their intrinsic properties, MSC display
great potential to be used as a real alternative source
for cellular therapy in many degenerative diseases,
including T1D.
Much has been achieved in the past 5 yr in the field
of stem cells. However, there is no reliable cell source
that could be used for the cell-based therapy of diabetes
mellitus, so far. In what concerns reprogramming of
MSC into functional insulin-producing phenotypes,
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there are still a few resources to be explored.
Once adequate mechanisms for cell-based therapy are
established and tools are successfully applied, it will
be possible to obtain cells capable of regenerating or
replacing the missing pancreatic β-cells.
It is quite clear that the cure of diabetes will require
a combination of distinct strategies. Cell-based thera-
pies may recover endogenous insulin production; yet,
modulation of the autoimmune disease behind T1D is
essential to achieve an effective and long-lasting ther-
apeutic intervention. Also, β-cell proliferating agents,
such as incretin analogs and islet neogenesis-associated
protein, might be of benefit when used simultaneously
to cell-based therapies, more so on advanced stages
of β-cell destruction. Hence, to achieve the goal of
permanent insulin independence, work on distinct but
complementary research lines has still to go further.
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